Selective proteasome inhibitors : modulators of antigen presentation?

Zitieren

Dateien zu dieser Ressource

Dateien Größe Format Anzeige

Zu diesem Dokument gibt es keine Dateien.

GRÖTTRUP, Marcus, Gunter SCHMIDTKE, 1999. Selective proteasome inhibitors : modulators of antigen presentation?. In: Drug Discovery Today. 4(2), pp. 63-71. ISSN 1359-6446. eISSN 1878-5832

@article{Grottrup1999Selec-22238, title={Selective proteasome inhibitors : modulators of antigen presentation?}, year={1999}, doi={10.1016/S1359-6446(98)01292-6}, number={2}, volume={4}, issn={1359-6446}, journal={Drug Discovery Today}, pages={63--71}, author={Gröttrup, Marcus and Schmidtke, Gunter} }

<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/22238"> <dc:rights>deposit-license</dc:rights> <dcterms:title>Selective proteasome inhibitors : modulators of antigen presentation?</dcterms:title> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-27T13:34:18Z</dc:date> <dc:contributor>Schmidtke, Gunter</dc:contributor> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/22238"/> <dc:creator>Schmidtke, Gunter</dc:creator> <dcterms:bibliographicCitation>Drug Discovery Today ; 4 (1999), 2. - S. 63-71</dcterms:bibliographicCitation> <dc:contributor>Gröttrup, Marcus</dc:contributor> <dcterms:issued>1999</dcterms:issued> <dc:creator>Gröttrup, Marcus</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-03-27T13:34:18Z</dcterms:available> <dcterms:rights rdf:resource="http://nbn-resolving.org/urn:nbn:de:bsz:352-20140905103605204-4002607-1"/> <dcterms:abstract xml:lang="eng">The proteasome is the main nonlysosomal endoprotease in the cytoplasm and nucleus of all eukaryotic cells. It is responsible for the generation of most antigenic peptides as ligands for major histocompatibility complex (MHC) class I proteins. The proteasome hence qualifies as a target for modifying or silencing antigen processing and presentation to cytotoxic T cells, which are important players in transplant rejection and autoimmune disease. The authors summarize recent progress in the understanding of antigen processing by the proteasome and discuss the potential of novel and selective proteasome inhibitors as drugs for suppressing or modifying the cytotoxic immune response.</dcterms:abstract> <dc:language>eng</dc:language> </rdf:Description> </rdf:RDF>

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto